Access

News

Nature 402, 6 (4 November 1999) | doi:10.1038/46865

Open Innovation Challenges

naturejobs

NIH panel to limit secrecy on gene therapy

Meredith Wadman

The US government advisory committee that monitors experiments in human gene therapy plans to act early next month to stiffen its guidelines on the reporting of deaths and adverse events.The action by the Recombinant DNA Advisory Committee (RAC) of the National Institutes of Health (NIH) follows attempts by a leading researcher and a drug company to keep confidential a death and serious side effects, respectively, suffered by gene therapy patients.